Section 63M-2.054 - Methicillin Resistant Staphylococcus Aureas (MRSA)(1) Each facility's DHA or designee shall be responsible for infection control requirements in accordance with the CDC for the identification, evaluation, treatment and containment of Methicillin-Resistant Staphylococcus Aureus (MRSA).(2) Youth with open skin infections shall be referred to the DHA, or designee, PA or ARNP for a medical evaluation.(3) A MRSA infection shall be considered in the differential diagnosis of all youth presenting with skin and soft tissue infections consistent with a staphylococcal infection.(4) The DHA or designee or PA or ARNP shall determine the necessity for wound incision and drainage, use of warm compresses, and the need for antibiotic therapy.(5) The DHA shall re-evaluate a youth at least one week after completion of antibiotic therapy for recurrent skin lesions and/or wound assessment to determine the need for further re-culture and treatment.(6) Standard Precautions and/or Contact Precautions shall be used for all care for the prevention of cross-contamination of infection.(7) Each facility shall implement environmental sanitation for maintaining infection control and preventing the spread of MRSA infection to others.(8) Any youth with a skin infection shall receive infection control education that includes prevention and cross-contamination of infection.Fla. Admin. Code Ann. R. 63M-2.054
Rulemaking Authority 985.64(2) FS. Law Implemented 985.64(2), 985.145, 985.18 FS.